* Cellebrite DI Ltd CLBT.OQ CLBT.O is expected to show a
rise
in quarterly revenue when it reports results on August 15 for
the period ending June 30 2024
* The Petah Tikva Israel-based company is expected to
report a
19.6% increase in revenue to $91.713 million from $76.68 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Cellebrite DI Ltd is for
earnings of 5 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cellebrite
DI Ltd
is $14.50, above its last closing price of $13.34.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 0.05 0.06 0.08 Beat 42.9
Dec. 31 2024 0.05 0.06 0.11 Beat 89.7
Sep. 30 2023 0.05 0.05 0.10 Beat 118.9
Jun. 30 2023 0.02 0.02 0.05 Beat 114.3
Mar. 0.02 0.02 0.04 Beat 77.8
31 2023
Dec. 31 2022 0.03 0.04 0.08 Beat 100
Sep. 30 2022 0.02 0.02 0.01 Missed -55.6
Jan. 1 0001 0.02 0.03 0.00 Missed -100
This summary was machine generated August 13 at 13:54 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)